BRPI0717077A2 - Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh) - Google Patents

Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh) Download PDF

Info

Publication number
BRPI0717077A2
BRPI0717077A2 BRPI0717077-7A BRPI0717077A BRPI0717077A2 BR PI0717077 A2 BRPI0717077 A2 BR PI0717077A2 BR PI0717077 A BRPI0717077 A BR PI0717077A BR PI0717077 A2 BRPI0717077 A2 BR PI0717077A2
Authority
BR
Brazil
Prior art keywords
tsh
patient
pharmaceutical composition
rhtsh
serum
Prior art date
Application number
BRPI0717077-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Eliana Clark
James Magner
Jeffrey Skell
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI0717077A2 publication Critical patent/BRPI0717077A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0717077-7A 2006-09-19 2007-09-18 Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh) BRPI0717077A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84607706P 2006-09-19 2006-09-19
US60/846,077 2006-09-19
PCT/US2007/020221 WO2008036271A1 (en) 2006-09-19 2007-09-18 Formulations for therapeutic administration of thyroid stimulating hormone (tsh)

Publications (1)

Publication Number Publication Date
BRPI0717077A2 true BRPI0717077A2 (pt) 2013-11-26

Family

ID=39018092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717077-7A BRPI0717077A2 (pt) 2006-09-19 2007-09-18 Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh)

Country Status (13)

Country Link
US (1) US20100048455A1 (enExample)
EP (1) EP2063909B1 (enExample)
JP (1) JP2010503689A (enExample)
AR (1) AR062894A1 (enExample)
BR (1) BRPI0717077A2 (enExample)
CA (1) CA2663323A1 (enExample)
DK (1) DK2063909T3 (enExample)
ES (1) ES2396502T3 (enExample)
MX (1) MX2009002985A (enExample)
PL (1) PL2063909T3 (enExample)
PT (1) PT2063909E (enExample)
SI (1) SI2063909T1 (enExample)
WO (1) WO2008036271A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793948B1 (en) * 2011-12-19 2022-03-23 Genzyme Corporation Thyroid stimulating hormone compositions
ES2947985T3 (es) * 2017-12-14 2023-08-25 The London Psychiatry Centre Tratamiento de la depresión resistente mediante la aplicación de estimulación magnética transcraneal repetitiva con tratamiento con hormona tiroidea
CN113740523A (zh) * 2021-09-14 2021-12-03 首都医科大学附属北京朝阳医院 一种基于量值溯源的tsh多系统赋值方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0228604A3 (en) * 1985-12-11 1988-10-12 Sloan-Kettering Institute For Cancer Research Isolation of a gene encoding human thyrotropin beta subunit
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
KR100642599B1 (ko) * 1997-09-22 2006-11-10 유니버시티 어브 메릴랜드, 발티모어 갑상선 자극 호르몬의 변이체 및 이에 근거한 방법
CN1321092A (zh) * 1998-06-30 2001-11-07 安姆根有限公司 用于生物活性剂的延缓给药的热敏生物可降解水凝胶
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
US20080167223A1 (en) * 2004-04-16 2008-07-10 Mount Sinai School Of Medicine Methods and Compositions for Using Tsh in the Inhibition of Tnf Activity

Also Published As

Publication number Publication date
ES2396502T3 (es) 2013-02-22
JP2010503689A (ja) 2010-02-04
SI2063909T1 (sl) 2013-02-28
EP2063909B1 (en) 2012-10-24
US20100048455A1 (en) 2010-02-25
MX2009002985A (es) 2009-04-01
DK2063909T3 (da) 2013-01-02
AR062894A1 (es) 2008-12-10
PT2063909E (pt) 2013-01-15
EP2063909A1 (en) 2009-06-03
WO2008036271A1 (en) 2008-03-27
PL2063909T3 (pl) 2013-05-31
CA2663323A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
JP2022169550A (ja) ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物
Cao et al. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
Frenken et al. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection
JP2010518170A (ja) 冠微小血管疾患の処置のためのラノラジンの使用
BR112020012766A2 (pt) medicamento para tratar câncer
JP2010053145A (ja) 血管形成的に有効なｆｇｆ−２の単位用量および使用方法
BR102016000829A2 (pt) composições e métodos para tratamento de articulações
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
US20250262225A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
US20020019336A1 (en) Sustained release drug compositions
JP2023533129A (ja) 非プロトン性極性溶媒中の安定な持続放出治療組成物およびその製造方法
BRPI0717077A2 (pt) Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh)
US5834451A (en) Remedy for myotonic dystrophy
US20250152674A1 (en) Oral octreotide for treatment of disease
Zhao et al. 20-Week intramuscular toxicity study of rotigotine behenate extended-release microspheres for injection via intramuscular injection in cynomolgus monkeys
MD3746047T2 (ro) Compoziție injectabilă
KR20200103029A (ko) 1 형 당뇨병 및 인슐린을 사용하는 2 형 당뇨병에서 운동-유발성 저혈당증의 치료
US12343383B2 (en) High concentration insulin formulation
BR102023017529A2 (pt) Compostos do hormônio paratireoide no tratamento do hipoparatireoidismo
EP4654986A1 (en) Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
WO2023151638A1 (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途
CN109172600A (zh) 一种药物组合物及其用途
OA19845A (en) Injectable composition.
BR122025006444A2 (pt) Formulações tamponadas de exendina (9-39)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]